A newly published paper from the Memorial Sloan-Kettering Cancer Center group in New York has proposed a predictive model which might allow a high percentage of candidates for active surveillance as initial management to skip a second, confirmatory biopsy after initial diagnosis. … READ MORE –
Filed under: Diagnosis, Management, Risk | Tagged: active, confirmatory, model, predictive, rebiopsy, surveillance | Leave a comment »
So a research study from the Keck School of Medicine of the University of Southern California has provided some very preliminary information about the utility of 3D printed models as surgical aids to radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: aid, model, printed, surgery, three-dimensional | Leave a comment »
A newly published paper in the journal PLoSOne has addressed the future prevalence of various different clinical states of prostate cancer here in the USA, along with the mortality of the men diagnosed with prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: estimate, incidence, model, mortality, prevalence | Leave a comment »
A new study just published online in the journal Cancer Discovery has helped to clarify — or perhaps “clarify” is the wrong word — just how complex risk for prostate cancer really is. … READ MORE …
Filed under: Uncategorized | Tagged: genetic, model, profile, risk | 6 Comments »
Researchers at Weill Medical College and at Memorial Sloan-Kettering Cancer Center in New York have worked out how to grow “organoids” from metastatic prostate cancer tissue. This may be important for the clinical testing of new types of treatment and (later on) for the ability to determine which drugs work well in individual patients. … READ MORE …
Filed under: Uncategorized | Tagged: in vitro, model, organoid, test | Leave a comment »
There was an intriguing paper in the November 2013 issue of the journal Prostate suggesting that intermittent dosing with testosterone in between doses of androgen deprivation therapies may actually help men in the early stages of castration resistance to respond better to treatment over time. … READ MORE …
Filed under: Uncategorized | Tagged: boost, castration-resistance, CRPC, hypothesis, model, teststerone | 4 Comments »
An article by a respected group of researchers at the University of Texas M. D. Anderson Cancer Center in Houston, published in the August issue of Cancer Discovery, proposes a new classification system for progression of prostate cancer over time. This has implications for the appropriate development and use of markers for use in treatment and drug development. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: classification, markers, mechanism, model, progression | 6 Comments »
A paper just published on line in Clinical Cancer Research has attempted to project the prostate cancer-specific mortality rates of men managed by active surveillance (followed by radical prostatectomy if and when necessary) as compared to the disease-specific mortality rates of men treated with an immediate radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, model, outcome, surgery | 14 Comments »
For those who are really “into” the probabilistic statistics of prostate cancer decision analysis, we recommend a recent article in the journal Medical Decision-Making. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: analysis, decision, Markov, model, PSA, screening | 7 Comments »
According to reports on a number of science web sites today, a group of researchers at the University of Illinois at Chicago has developed an interesting new model which may be useful in exploring the prevention and treatment of prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: laboratory, model, prostsphere | Leave a comment »
In February this year Efstathiou and Logothetis published an article in Clinical Cancer Research stating that the traditional model of cancer drug development — seeking agents that had some activity in very later stages of the cancer and then “working backwards” to explore the effects of these agents earlier in the disease — had been ineffective in prostate cancer. … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: development, drug, hypothesis, model | 1 Comment »
Dr. Guy Dimonte is a specialist in fluid dynamics who works at the Los Alamos National Laboratory in New Mexico. He has recently applied the mathematical approaches used to model dynamic systems to develop a new model for the progression of prostate cancer from diagnosis onwards. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk | Tagged: model, prognosis, progression | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 